1197166-08-7

Upstream product

• 6601-22-5 2,6-Dichloro-4-morpholino-1,3,5-triazine 
• 1332327-23-7 (S)-4-(4-chloro-6-(tetrahydrofuran-3-yloxy)-1,3,5-triazin-2-yl)morpholine 
• 51-08-1 4-amino-N-(2-(piperidin-1-yl)ethyl)benzamide 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 1332327-21-5 (S)-4-(4-morpholino-6-(tetrahydrofuran-3-yloxy)-1,3,5-triazin-2-yl)aniline 

Relevant academic research and scientific papers

Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors

We recently described several highly potent, triazine (1) and triazolopyrimidine (2) scaffold-based, dual PI3K/mTOR-inhibitors (e.g., 1, PKI-587) that were efficacious in both in vitro and in vivo models. In order to further optimize these compounds we devised a novel series, the 2-oxatriazines, which also exhibited excellent potency and good metabolic stability. Some 2-oxatriazines showed promising in vivo biomarker suppression and induced apoptosis in the MDA-MB-361 breast cancer xenograft model.